Format

Send to

Choose Destination
Expert Opin Ther Targets. 2016 Jun;20(6):755-66. doi: 10.1517/14728222.2016.1126248. Epub 2016 Jan 8.

Pyruvate dehydrogenase as a therapeutic target for obesity cardiomyopathy.

Author information

1
a Division of Cardiovascular Medicine, Radcliffe Department of Medicine , University of Oxford , Oxford , OX3 9DU , UK.
2
b Department of Physiology , Anatomy and Genetics, University of Oxford , Sherrington Road, Oxford , OX3 9DU , UK.

Abstract

INTRODUCTION:

Obesity cardiomyopathy is a major public health problem with few specific therapeutic options. Abnormal cardiac substrate metabolism with reduced pyruvate dehydrogenase (PDH) activity is associated with energetic and functional cardiac impairment and may be a therapeutic target.

AREAS COVERED:

This review summarizes the changes to cardiac substrate and high energy phosphorus metabolism that occur in obesity and describes the links between abnormal metabolism and impairment of cardiac function. The available evidence for the currently available pharmacological options for selective metabolic therapy in obesity cardiomyopathy is reviewed.

EXPERT OPINION:

Pharmacological restoration of PDH activity is in general associated with favourable effects upon cardiac substrate metabolism and function in both animal models and small scale human studies, supporting a potential role as a therapeutic target.

KEYWORDS:

Obesity; heart failure; imaging; metabolism

PMID:
26617082
DOI:
10.1517/14728222.2016.1126248
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center